Søren Kragh Moestrup

"Development of an antibody-drug conjugate therapy for treatment of NASH – from molecular discoveries to animal studies"

Søren Kragh Moestrup
29/11 2017
12:15-13:15, Danish IAS conference room (Ø18-509-1)

Non-alcoholic steatohepatitis (NASH) is an epidemic inflammatory liver disease closely connected to obesity and the increasing consumption of high-caloric carbohydrates in soft drinks and food. So far, no effect medical therapy exists.

We have now developed a new antibody-based drug therapy targeting in liver macrophages and with profound effect in experimental NASH. The lecture will describe the drug development from the early molecular identification of the macrophage target (CD163) to animal studies and future plans.